Biotechnology opens up new avenues for detecting relapses and developing treatments for lung cancer
- Lung cancer remains one of the major public health challenges. In 2024, 2.6 million new cases and 1.9 million deaths were recorded worldwide.
- Biotechnology is driving the development of new tools to improve patient monitoring and develop more precise and personalised therapeutic alternatives.
- On the occasion of International Lung Cancer Awareness Day, we highlight the work of our members Flomics Biotech and Oryzon Genomics in detecting relapses through liquid biopsy and artificial intelligence, and developing new epigenetics-based therapies, respectively.
Tuesday, 17 November 2026, Madrid, Spain. – Lung cancer continues to be one of the greatest public health challenges due to its high incidence and mortality rates. According to the latest estimates from the International Agency for Research on Cancer (IARC), approximately 2.6 million new cases were diagnosed worldwide in 2024, and around 1.9 million deaths were recorded. In Spain, the report Cancer Figures in Spain 2026 estimates that 34,908 new cases will be diagnosed this year.
Against this backdrop, biotechnology is driving the development of new tools to improve patient monitoring and develop more precise and personalised therapeutic alternatives. On the occasion of International Lung Cancer Awareness Day, observed every year on 17 November, the Spanish Association of Biocompanies (AseBio) highlights the work of two of its members, Flomics Biotech and Oryzon Genomics, which are researching innovative solutions to address some of the main challenges posed by this disease.
Liquid biopsy and artificial intelligence to detect relapses
One of the main challenges in lung cancer is detecting potential relapses before they become visible through imaging tests. Liquid biopsy offers new opportunities to identify tumour signals through a blood sample, although detecting them at early stages remains challenging.
To address this challenge, Flomics Biotech is coordinating LUMINA, a European project funded by the Eurostars programme that is developing a tool to detect minimal residual disease in patients with stage I to III lung adenocarcinoma. The initiative combines information from circulating cell-free DNA and RNA with artificial intelligence to integrate multiple molecular signals and facilitate patient monitoring.
As Esther Lizano, co-founder and Business Development Director at Flomics Biotech, explains, “the future lies in combining several layers of molecular information, rather than relying solely on circulating tumour DNA”.
The project has completed agreements to access patient plasma samples from biobanks, is preparing to collect new samples and has begun adapting its mutation detection software to analyse circulating cell-free DNA and RNA. Its goal is to move towards earlier detection of relapses and support clinical decision-making.
New epigenetics-based therapeutic strategies
Meanwhile, Oryzon Genomics is researching new therapeutic alternatives for small cell lung cancer, one of the most aggressive and difficult-to-treat tumours due to its rapid growth, ability to spread and frequent development of treatment resistance.
One of the company's research areas focuses on iadademstat, an LSD1 inhibitor. LSD1 is an epigenetic enzyme involved in regulating genes associated with cell proliferation and differentiation. Preclinical studies suggest that this compound could interfere with mechanisms that promote tumour growth and increase the sensitivity of tumour cells to the immune response.
Currently, iadademstat is being evaluated in two clinical trials in the United States. The first, a Phase I/II trial sponsored by the National Cancer Institute (NCI), is investigating its combination with immune checkpoint inhibitors. The second, a Phase Ib trial led by Yale University, is studying its combination with atezolizumab and radiotherapy.
As Jordi Xaus, Chief Scientific Officer (CSO) at Oryzon Genomics, points out, “our goal is to develop new combination strategies that can overcome some of the limitations of current therapies and improve patient outcomes”.
Although the clinical efficacy of iadademstat still needs to be confirmed, both research approaches highlight the potential of biotechnology to advance towards more precise and personalised medicine by developing tools to improve patient monitoring and exploring new treatment options for lung cancer.
The Spanish Association of Biocompanies (AseBio) brings together 370 organisations and represents the Spanish biotechnology sector as a whole. Its mission is to lead the country's transformation by positioning science, innovation and, in particular, biotechnology as drivers of economic growth and social well-being. Its members include companies, associations, foundations, universities, technology centres and research institutions whose activities are directly or indirectly related to biotechnology in Spain.